# A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

> **NCT01732198** · PHASE2 · UNKNOWN · sponsor: **Nuron Biotech Inc.** · enrollment: 220 (estimated)

## Conditions studied

- Infectious Disease

## Interventions

- **BIOLOGICAL:** NU300
- **BIOLOGICAL:** ActHIB
- **BIOLOGICAL:** Prevnar 13

## Key facts

- **NCT ID:** NCT01732198
- **Lead sponsor:** Nuron Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2014-01
- **Final completion:** 2014-04
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2013-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732198, "A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01732198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*